Risk categorization of AML based on karyotyping of leukemic blasts has become routine. Mutations in NPM1, CCAAT enhancer-binding protein-α (with double-mutations) and FCT3-internal tandem ...

NGS-based AML MRD is being more widely adopted in drug development ... customers to detect key AML-relevant biomarkers, including NPM1 and FLT3-ITDs, at extremely low levels.